SAB Biotherapeutics (NASDAQ:SABS) has seen a positive shift in its stock outlook, with analysts at Chardan Capital raising their price target from $12.00 to $14.00. This adjustment, announced in a report released on Wednesday, indicates a potential upside of 205.01% from the stock’s previous closing price. Chardan Capital has maintained a “buy” rating on the stock, reflecting growing confidence in the company’s future prospects.
Several other financial institutions have also recently provided updates on SAB Biotherapeutics. Wall Street Zen upgraded its rating from “sell” to “hold” on November 22, 2023. Conversely, Weiss Ratings reaffirmed a “sell (d)” rating in a report dated December 29, 2023. On January 7, 2024, UBS Group initiated coverage with a “buy” rating and a target price of $7.00. Guggenheim followed suit, setting a target of $15.00 in its report on December 19, 2023. Meanwhile, HC Wainwright lowered its price target from $9.00 to $7.00, while maintaining a “buy” rating.
As of now, one research analyst has assigned a “Strong Buy” rating to SAB Biotherapeutics, four have given it a “Buy” rating, and one has classified it as a “Sell.” According to data from MarketBeat.com, the stock currently holds an average rating of “Moderate Buy” with a mean price target of $10.00.
Stock Performance and Financial Metrics
On Wednesday, shares of SAB Biotherapeutics opened at $4.59. The company has a market capitalization of $233.86 million, a price-to-earnings ratio of -1.98, and a beta of 0.59. The firm maintains a low debt-to-equity ratio of 0.02, with a current ratio of 9.46 and a quick ratio of 10.50. Over the past year, the stock has experienced a low of $1.00 and a high of $6.60.
SAB Biotherapeutics disclosed its latest earnings results on March 9, 2024, reporting an earnings per share (EPS) of ($0.46), which fell short of analysts’ expectations of ($0.16) by ($0.30). Analysts predict that the company will report an EPS of ($3.69) for the current fiscal year.
Investor Interest in SAB Biotherapeutics
Recent activity from institutional investors suggests growing interest in SAB Biotherapeutics. ADAR1 Capital Management LLC acquired a new position valued at approximately $30,000 during the third quarter. Similarly, Dimensional Fund Advisors LP invested around $32,000 during the same period. The State of Wyoming and Virtu Financial LLC also made new investments valued at $34,000 and $40,000, respectively. Furthermore, State Street Corp acquired a stake worth about $49,000 in the fourth quarter.
Currently, institutional investors and hedge funds own 7.82% of SAB Biotherapeutics stock, reflecting a cautious but increasing interest from larger investment entities.
SAB Biotherapeutics, headquartered in Sioux Falls, South Dakota, is a clinical-stage biotechnology company focused on developing fully human polyclonal antibody therapeutics. Its proprietary Tc Bovine® platform utilizes genetically engineered cattle to produce large quantities of human antibodies aimed at specific infectious agents or disease-related antigens. This innovative approach seeks to combine the broad-spectrum efficacy of polyclonal antibody therapies with the necessary scalability for clinical and commercial applications.
The company’s leading programs primarily target infectious diseases, positioning it strategically within the biotechnology sector as it seeks to expand its market presence.
